Cytokinetics, Incorporated2024财年第三财季实现净利润-1.61亿美元，同比减少24.81%

市场透视11-16

11月16日，Cytokinetics, Incorporated（CYTK.US）公布财报，公告显示公司2024财年第三财季净利润为-1.61亿美元，同比减少24.81%；其中营业收入为463000.00美元，同比增加22.49%，每股基本收益为-1.36美元。从资产负债表来看，Cytokinetics, Incorporated（CYTK.US）总负债14.50亿美元，其中短期债务30.38...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2483306429?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-16 00:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2483306429","market":"us","top_or_hot":-1,"title":"Cytokinetics, Incorporated2024财年第三财季实现净利润-1.61亿美元，同比减少24.81%","media":"市场透视","content":"<div>\n<p>11月16日，Cytokinetics, Incorporated（CYTK.US）公布财报，公告显示公司2024财年第三财季净利润为-1.61亿美元，同比减少24.81%；其中营业收入为463000.00美元，同比增加22.49%，每股基本收益为-1.36美元。从资产负债表来看，Cytokinetics, Incorporated（CYTK.US）总负债14.50亿美元，其中短期债务30.38...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116000111abc513e0&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cytokinetics, Incorporated2024财年第三财季实现净利润-1.61亿美元，同比减少24.81%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCytokinetics, Incorporated2024财年第三财季实现净利润-1.61亿美元，同比减少24.81%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-16 00:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116000111abc513e0&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>11月16日，Cytokinetics, Incorporated（CYTK.US）公布财报，公告显示公司2024财年第三财季净利润为-1.61亿美元，同比减少24.81%；其中营业收入为463000.00美元，同比增加22.49%，每股基本收益为-1.36美元。从资产负债表来看，Cytokinetics, Incorporated（CYTK.US）总负债14.50亿美元，其中短期债务30.38...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116000111abc513e0&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CYTK","symbol_name":"Cytokinetics","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116000111abc513e0&s=b","article_id":"2483306429","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116000111abc513e0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2483306429","pubTimestamp":1731686423,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"11月16日，Cytokinetics, Incorporated公布财报，公告显示公司2024财年第三财季净利润为-1.61亿美元，同比减少24.81%；其中营业收入为463000.00美元，同比增加22.49%，每股基本收益为-1.36美元。从资产负债表来看，Cytokinetics, Incorporated总负债14.50亿美元，其中短期债务30.38百万美元，资产负债比为1.00，流动比率为9.27。机构评级：截至2024年11月16日，当前有17家机构对Cytokinetics, Incorporated目标价做出预测，其中目标均价为81.29美元，其中最低目标价为60.00美元，最高目标价为120.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"CYTK":"Cytokinetics"},"translate_title":"Cytokinetics, Incorporated achieved net profit of-$161 million in the third fiscal quarter of fiscal 2024, a year-on-year decrease of 24.81%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CYTK":1},"content_text":"11月16日，Cytokinetics, Incorporated（CYTK.US）公布财报，公告显示公司2024财年第三财季净利润为-1.61亿美元，同比减少24.81%；其中营业收入为463000.00美元，同比增加22.49%，每股基本收益为-1.36美元。从资产负债表来看，Cytokinetics, Incorporated（CYTK.US）总负债14.50亿美元，其中短期债务30.38百万美元，资产负债比为1.00，流动比率为9.27。机构评级：截至2024年11月16日，当前有17家机构对Cytokinetics, Incorporated目标价做出预测，其中目标均价为81.29美元，其中最低目标价为60.00美元，最高目标价为120.00美元。公司简介：细胞动力科技有限公司是一家生物技术公司，开发肌肉生物学驱动的治疗以肌肉功能降低、肌肉无力和疲劳为特征的疾病。该公司为肌萎缩性侧索硬化症、心力衰竭、脊髓性肌萎缩症和慢性阻塞性肺病等疾病开发治疗方法。这种治疗是基于专门设计的小分子来增加肌肉功能和收缩力。该公司正在开发肌肉导向的研究性药物，这些药物可能会改善患有破坏性心血管疾病和肌肉功能受损的神经肌肉疾病的人的健康寿命。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483306429"}